Abstract
Acute coronary syndromes and, in paticular, ST – segment elevation myocardial infarction are the principle causes or mortality and morbidity in the industrialized countries. The manadgement of acute myocadial infarction is much debated in the literature; primary percutaneous coronary intervention is the treatment of choice. In the recent years there has been an increasing interest in the concept of adjunctive pharmacological therapy to improve outcomes in primary percutaneous coronary intervention. In the literature randomized trials of intravenous or more recently intracoronary injection of glycoprotein IIb/IIIa inhibitors have provided conflicting results with no definitive evidence for efficacy. The aim of the report is to review the evidence to our date on the role of intracoronary injection of abciximab during primary percutaneous intervention in the setting of acute myocardial infarction.
Keywords: STEMI, Acute coronary syndrome, adjuvant therapy, bleeding, GP IIb/IIIa inhibitors, in – stent restenosis, no – reflow phenomenon, percutaneous coronary intervention, platelet, thrombosis.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Volume: 11 Issue: 2
Author(s): Andrea Rognoni, Alessadro Lupi, Chiara Cavallino, Roberta Rosso, Alessia Veia, Sara Bacchini and Angelo Sante Bongo
Affiliation:
Keywords: STEMI, Acute coronary syndrome, adjuvant therapy, bleeding, GP IIb/IIIa inhibitors, in – stent restenosis, no – reflow phenomenon, percutaneous coronary intervention, platelet, thrombosis.
Abstract: Acute coronary syndromes and, in paticular, ST – segment elevation myocardial infarction are the principle causes or mortality and morbidity in the industrialized countries. The manadgement of acute myocadial infarction is much debated in the literature; primary percutaneous coronary intervention is the treatment of choice. In the recent years there has been an increasing interest in the concept of adjunctive pharmacological therapy to improve outcomes in primary percutaneous coronary intervention. In the literature randomized trials of intravenous or more recently intracoronary injection of glycoprotein IIb/IIIa inhibitors have provided conflicting results with no definitive evidence for efficacy. The aim of the report is to review the evidence to our date on the role of intracoronary injection of abciximab during primary percutaneous intervention in the setting of acute myocardial infarction.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessadro, Cavallino Chiara, Rosso Roberta, Veia Alessia, Bacchini Sara and Bongo Angelo Sante, Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020003
DOI https://dx.doi.org/10.2174/1871525711311020003 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dissecting abdominal aortic aneurysm in Angiotensin II-infused mice: the importance of imaging
Current Pharmaceutical Design Computational Methods and Algorithms for Mass Spectrometry Based Differential Proteomics: Recent Advances, Perspectives and Open Problems
Current Proteomics Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mitochondrial-Targeted Antioxidants and Oxidative Stress: A Proteomic Prospective Study
Current Pharmaceutical Design Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Molecular Mechanism of Aggravation of Hypertensive Organ Damages by Short-Term Blood Pressure Variability
Current Hypertension Reviews Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation)
Current Vascular Pharmacology Fucose Specific Lectins in Cancer Research and Diagnosis
Drug Design Reviews - Online (Discontinued) Meet Our Editorial Board Member:
Current Vascular Pharmacology COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases
Current Pharmaceutical Design Enlarging the NSAIDs Family: Ether, Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Novel Anti-Inflammatory and Analgesic Agents
Current Medicinal Chemistry Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry The Endocannabinoid System in the Cancer Therapy: An Overview
Current Medicinal Chemistry